肾移植前心肌灌注显像的预后价值:移植后随访与结局
在1189例肾移植受者中,819例(69%)移植前接受了心肌灌注显像(MPI),182例(22%)MPI异常。中位随访56个月,异常MPI是心血管事件的独立预测因子(HR 1.78),血管扩张剂负荷心率反应迟钝(HRR)亦独立预测心血管事件(HR 1.73)和全因死亡(HR 2.26);MPI异常且移植前接受血运重建者移植后死亡率低。
要点
- 血管扩张剂负荷心率反应迟钝独立预测心血管事件(HR 1.73)和全因死亡(HR 2.26)。
- MPI异常且移植前接受血运重建者移植后年死亡率与MPI正常或无MPI者相似(1.9% vs 1.7-2.6%,p=0.2)。
核心结论
- 接受筛查MPI的肾移植受者中约五分之一MPI异常,异常MPI是心血管事件的独立预测因子。
- 血管扩张剂负荷心率反应迟钝与心血管事件和死亡风险增加相关,即使校正异常MPI后仍独立。
- MPI异常且移植前接受血运重建的患者移植后死亡风险低。
- MPI是肾移植前风险分层的有用工具。
研究设计与样本
- 在本机构连续纳入肾移植受者,评估移植前MPI(心肌灌注、左心室射血分数LVEF和心率反应HRR)对移植后结局的预后价值。
- MPI异常定义为存在灌注缺损或射血分数降低。
- 血管扩张剂负荷HRR以相对基线的百分比变化计算。
- 主要终点为移植后心血管死亡、心肌梗死和冠状动脉血运重建的复合终点;次要终点为全因死亡。
- 共1189例肾移植受者,819例(69%)接受了MPI。
主要发现
- 819例接受MPI者中,182例(22%)MPI异常,31例(4%)移植前接受了冠状动脉血运重建。
- 移植后中位随访56个月,无MPI、MPI正常和MPI异常患者的年心血管事件率分别为1.5%、3.1%和4.3%(p<0.001),年死亡率分别为1.8%、2.6%和3.6%(p=0.016)。
- MPI异常且移植前接受血运重建者年死亡率与无MPI或MPI正常者相似(1.9% vs 1.7-2.6%,p=0.2),而未接受血运重建者年死亡率更高(4% vs 1.7-2.6%,p=0.003)。
关键数值与推荐
- MPI异常定义:存在灌注缺损或射血分数降低。
- HRR计算:血管扩张剂负荷下相对基线的百分比变化。
- 主要终点:心血管死亡、心肌梗死和冠状动脉血运重建的复合终点。
- 次要终点:全因死亡。
临床怎么用
- 原文结论认为MPI是肾移植前风险分层的有用工具。
- 原文未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Noninvasive stress testing is commonly performed as part of pre-renal transplantation (RT) evaluation. We evaluated the prognostic value of myocardial perfusion imaging (MPI)-myocardial perfusion, left ventricular ejection fraction (LVEF) and heart rate response (HRR)-post-RT. METHODS: Consecutive RT recipients were identified at our institution. MPI was considered abnormal when there was a perfusion defect or reduced ejection fraction. HRR to vasodilator stress was calculated as percentage change from baseline. The primary outcome was a composite of cardiovascular (CV) death, myocardial infarction (MI) and coronary revascularization (CR) post-RT; all-cause mortality was the secondary endpoint. RESULTS: Among 1189 RT recipients, 819 (69%) underwent MPI. Of those, 182 (22%) had abnormal MPI, and 31 (4%) underwent CR pre-RT. During a median follow-up of 56 months post-RT, the annual CV event and mortality rates for patients who had no MPI, normal MPI and abnormal MPI were 1.5%, 3.1% and 4.3% (p < 0.001), and 1.8%, 2.6% and 3.6% (p = 0.016), respectively. After multivariate adjustment, compared to patients without MPI, the hazard ratios (HRs) for CV events for normal and abnormal MPI were 1.47 ([0.93-2.33], p = 0.1) and 1.78 ([1.03-3.06], p = 0.04). Blunted HRR was an independent predictor of CV events (HR = 1.73 [1.04-2.86], p = 0.034) and all-cause death (HR = 2.26 [1.28-3.98], p = 0.005) after adjusting for abnormal MPI. Patients with abnormal MPI who underwent CR pre-RT had annual mortality rates similar to those with no or normal MPI (1.9% vs. 1.7-2.6%, p = 0.2), while those who did not undergo CR had higher annual mortality (4% vs. 1.7-2.6%, p = 0.003). CONCLUSIONS: One in five RT recipients who underwent screening MPI had an abnormal study, an independent predictor of CV events. A blunted HRR to vasodilator stress was associated with increased risk of CV events and death, even after adjusting for abnormal MPI. Patients with abnormal MPI who underwent CR were at low risk of mortality following RT. MPI is a useful tool to aid in risk stratification pre-RT.
引用
- Ives CW, AlJaroudi WA, Kumar V, et al. Prognostic value of myocardial perfusion imaging performed pre-renal transplantation: post-transplantation follow-up and outcomes. Eur J Nucl Med Mol Imaging. 2018. PMID: 29882159. doi:10.1007/s00259-018-4068-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。